XML 67 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Acquisitions (Details Textual)
$ / shares in Units, $ in Millions
3 Months Ended 12 Months Ended
Sep. 26, 2023
USD ($)
ft²
$ / shares
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Business Acquisition [Line Items]          
Selling, general and administrative     $ 581.5 $ 605.0  
Goodwill     6,227.4   $ 6,219.2
Forecast          
Business Acquisition [Line Items]          
Payments to Acquire Businesses, Gross, Outstanding Equity Awards   $ 983.9      
Reata Pharmaceuticals, Inc          
Business Acquisition [Line Items]          
Price per share | $ / shares $ 172.50        
Consideration transferred $ 7,193.4        
Total transaction value 6,602.9        
Selling, general and administrative 196.4        
Research and development expense asset acquired 197.0        
Operating expenses 393.4        
Inventory 1,300.0   1,259.0    
Operating lease liabilities 151.8   151.8    
Operating lease assets $ 121.2   121.2    
Lease term 16 years        
Operating Lease Area | ft² 327,400        
Lessee, Operating Lease, Remaining Lease Term 15 years        
Fair Value Indefinite Lived Intangible Assets Discount Rate 14.30%        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Amortization Period 3 years        
Goodwill $ 473.5   473.5    
Business Combination, Consideration Transferred, Equity Compensation Pre-acquisition Services 590.5        
Adjustment, inventory     44.1    
Reata Pharmaceuticals, Inc | Secured Debt | The Credit Facility | Line of Credit          
Business Acquisition [Line Items]          
Long-term debt, gross 1,000.0        
Reata Pharmaceuticals, Inc | Selling, general and administrative          
Business Acquisition [Line Items]          
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed         $ 28.4
Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)          
Business Acquisition [Line Items]          
Intangible assets: 4,200.0   4,200.0    
Reata Pharmaceuticals, Inc | In-process research and development          
Business Acquisition [Line Items]          
Intangible assets: 2,300.0   2,300.0    
Reata Pharmaceuticals, Inc | Priority review voucher          
Business Acquisition [Line Items]          
Intangible assets: 100.0   100.0    
Reata Pharmaceuticals, Inc | Other clinical programs          
Business Acquisition [Line Items]          
Intangible assets: $ 40.0   $ 40.0